References of "DEROISY, Rita"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailHigh Prevalence of Low Femoral Bone Mineral Density in Elderly Women Living in Nursing Homes or Community-Dwelling: A Plausible Role of Increased Parathyroid Hormone Secretion
Reginster, Jean-Yves ULiege; Deroisy, Rita ULiege; Pirenne, H. et al

in Osteoporosis International (1999), 9(2), 121-8

The present study was designed to visit elderly women living in nursing homes and to compare their femoral neck bone mineral density (BMD) and circulating levels of parathyroid hormone (PTH) and 25-OH ... [more ▼]

The present study was designed to visit elderly women living in nursing homes and to compare their femoral neck bone mineral density (BMD) and circulating levels of parathyroid hormone (PTH) and 25-OH vitamin D (25-OHD) with those of subjects living at home, in the immediate vicinity of the nursing homes. Of 1483 women, aged 70 years and older, who were selected, 993 agreed to participate in this trial. Their femoral neck BMD (n = 993) was measured by dual-energy X-ray absorptiometry, with a specific device installed in a mobile truck. The circulating levels of 25-OHD and PTH were assessed after an overnight fast (n = 748). After stratification for age, there were no significant differences in mean femoral neck BMD values, prevalence of femoral neck osteoporosis, mean serum 25-OHD and prevalence of absolute or relative 25-OHD deficiency between the two groups. Serum levels of PTH were significantly higher in women over 80 years old living in nursing homes, compared with the community-dwelling women. After adjustment for age, a significant relation was found between femoral neck BMD and PTH levels in the whole population (p = 0.004) and in community-dwelling subjects (p = 0.039). When stratifying our population by quartiles of serum PTH values, the odds ratios for femoral neck osteoporosis were significantly increased for the top two quartiles compared with the lowest one both before (p = 0.00146) and after (p = 0.0013) adjustment for age and type of housing. From this study we conclude that femoral osteoporosis is largely underestimated in European women. Living in a nursing home is not, per se, a risk factor for decreased femoral BMD, and circulating PTH levels are a key determinant of low femoral bone density and osteoporosis. [less ▲]

Detailed reference viewed: 20 (3 ULiège)
Peer Reviewed
See detailDepressive vulnerability is not an independent risk factor for osteoporosis in postmenopausal women.
Reginster, Jean-Yves ULiege; Deroisy, Rita ULiege; Paul, I. et al

in Maturitas (1999), 33(2), 133-7

Major depression has been repeatedly but not consistently reported to be associated with low bone mineral density (BMD) and to an increased risk for fracture in women. We have investigated, in healthy ... [more ▼]

Major depression has been repeatedly but not consistently reported to be associated with low bone mineral density (BMD) and to an increased risk for fracture in women. We have investigated, in healthy postmenopausal women, whether depressive symptomatology, assessed by the General Health Questionnaire (GHQ), was associated to a significant decrease in BMD, hence supporting the hypothesis of an independent pathogenetic link between the two disorders. We investigated 121 postmenopausal women, aged 48-77 years, spontaneously attending a screening visit for osteoporosis in an outpatient facility. BMD of the spine and the non-dominant hip (total and neck areas) were measured by Dual Energy X-Ray absorptiometry. All subjects completed to the 'General Health Questionnaire' translated and validated in French. No significant correlations were observed between the GHQ score and BMD of the spine (P = 0.54), the total hip area (P = 0.65), or the femoral neck area (P = 0.65). No differences in terms of spinal or femoral BMD were observed between women with GHQ score < 5 or > or = 5. When comparing values of BMD between women within the upper and the lower quartiles for GHQ score, no difference was observed for spine (P = 0.69), total hip (P = 0.80), or femoral neck (P = 0.93). Similarly, GHQ scores were not significantly different when comparing women in the upper and lower quartiles of BMD distribution at the spine or the hip. In conclusion, notwithstanding the clinical pattern of postmenopausal osteoporosis can lead to depression and, on the other hand, hormonal and behavioral disturbances reported in depression might be enhancing factors for accelerated bone loss, our present results do not support the hypothesis that otherwise healthy postmenopausal women with increased depressive complaints are also more prone to exhibit osteoporotic fractures. [less ▲]

Detailed reference viewed: 27 (4 ULiège)
Peer Reviewed
See detailParathyroid hormone plasma concentration in response to low 25-OH vitamin D circulating levels increase with age in elderly women
DEROISY, Rita ULiege; Taquet, AN; Dewe, W et al

in Osteoporosis International (1998), 8(S3), 40

Detailed reference viewed: 21 (1 ULiège)
Full Text
Peer Reviewed
See detailComparison of the short-term effects of three oral calcium vitamin D formulations and placebo on calcium metabolism
DEROISY, Rita ULiege; Collette, Julien ULiege; Albert, Adelin ULiege et al

in Current Therapeutic Research (1998), 59(6), 370-378

Detailed reference viewed: 18 (1 ULiège)
Full Text
Peer Reviewed
See detailEffects of two 1-year calcium and vitamin D3 treatments on bone remodeling markers and femoral bone density in elderly women
DEROISY, Rita ULiege; Collette, Julien ULiege; Chevalier, T et al

in Current Therapeutic Research (1998), 59(12), 850-862

Detailed reference viewed: 24 (1 ULiège)
Full Text
Peer Reviewed
See detailParathyroid hormone plasma concentrations in response to low 25-OH vitamin D circulating levels increases with age in elderly women.
Reginster, Jean-Yves ULiege; Frederick, I.; Deroisy, Rita ULiege et al

in Osteoporosis International (1998), 8(4), 390-2

Detailed reference viewed: 17 (3 ULiège)
Peer Reviewed
See detailIncreased parathyroïd hormone secretions as a risk factor for femoral osteoporosis in elderly women
Deroisy, Rita ULiege; Collette, Julien ULiege; Dewe, W. et al

in Osteoporosis International (1998), 8(S3), 40

Detailed reference viewed: 26 (9 ULiège)
Full Text
Peer Reviewed
See detailPlasma Estradiol Concentrations and Pharmacokinetics Following Transdermal Application of Menorest 50 or Systen (Evorel) 50
Reginster, Jean-Yves ULiege; Albert, Adelin ULiege; Deroisy, Rita ULiege et al

in Maturitas (1997), 27(2), 179-86

OBJECTIVES: In order to compare the pharmacokinetics of two transdermal estrogen replacement therapy (ERT) systems designed to release 50 micrograms 17 beta-estradiol/day, two studies were performed in ... [more ▼]

OBJECTIVES: In order to compare the pharmacokinetics of two transdermal estrogen replacement therapy (ERT) systems designed to release 50 micrograms 17 beta-estradiol/day, two studies were performed in healthy postmenopausal volunteers. METHODS: Both studies had a cross-over design and incorporated a 1-week wash-out period between treatments. In the first study, Menorest 50 and Systen 50 (Evorel 50) were compared over four days of application in 30 women. In the second, 13 women wore each of the two systems for a total of 12 days each (three patches each for 4 days), and comparison was made during the third patch period (steady state, between days 8 and 12). Plasma 17 beta-estradiol levels were assayed using specific direct radioimmunoassays, and pharmacokinetic parameters were calculated by standard methods. All the samples of the first study were re-analysed using a different radioimmunoassay and the results of both assays were compared. RESULTS: In both studies, plasma 17 beta-estradiol levels rose at a comparable rate and reached similar peak levels with each of the two formulations. Levels then remained relatively constant throughout both evaluation periods with Menorest 50, but began to decline after 12 hours in the first study and after 30 h under steady state conditions in the second study with Systen 50. The difference between the two products was statistically significant in both studies. Analysis of pharmacokinetic parameters confirmed the greater bioavailability of Menorest 50. In addition, 17 beta-estradiol levels remained within the suggested therapeutic ranges for relief of acute symptoms and protection against osteoporosis for longer periods of time with Menorest 50 than with Systen 50. CONCLUSION: Since the acute efficacy, long-term protective effects, side effects and risks associated with ERT may depend on critical threshold plasma levels, much attention should be paid to the pharmacokinetic profiles of different formulations. The comparison of these two different radioimmunoassays demonstrates the comparability of their results. [less ▲]

Detailed reference viewed: 47 (1 ULiège)
Full Text
Peer Reviewed
See detailAcute Changes in Serum Calcium and Parathyroid Hormone Circulating Levels Induced by the Oral Intake of Five Currently Available Calcium Salts in Healthy Male Volunteers
Deroisy, Rita ULiege; Zartarian, M.; Meurmans, L. et al

in Clinical Rheumatology (1997), 16(3), 249-53

Several calcium supplements are currently available and many of them are marketed without proper comparison of the bioavailability of the actual preparations. The aim of the present trial was to evaluate ... [more ▼]

Several calcium supplements are currently available and many of them are marketed without proper comparison of the bioavailability of the actual preparations. The aim of the present trial was to evaluate and compare the acute changes in serum calcium (Ca) and parathyroid hormone (PTH) levels following the oral administration of a vehicle and of five calcium salts currently prescribed in Western Europe. No significant changes in serum Ca or PTH levels were observed after administration of the vehicle. All calcium salts induced significant increases in serum Ca and decreases in serum PTH compared to baseline values. Comparison of the six response curves revealed a significantly greater increase in serum Ca and a greater decrease in serum PTH after each of the calcium salts than observed after the vehicle. However, no statistically significant differences were observed between the different calcium salts for serum Ca increments. The decrease in serum PTH observed after administration of an ossein-hydroxyapatite complex was significantly less important than after the four other calcium salts, even if statistically different than after vehicle. When assessing the area under the curve (AUC) of PTH values, we observed that calcium carbonate and citrate induce a significantly greater decrease in serum PTH than the other calcium salts which are, however, statistically more active than the vehicle. Serum PTH is decreased under the lower limit of the normal range (10 pg/ml), between t60 and t120 for calcium carbonate and citrate and between t60 and t90 for calcium gluconolactate while the mean PTH values remain within the normal range throughout the study with calcium pidolate, the ossein-hydroxyapatite complex and the vehicle. In conclusion, all calcium preparations significantly increase serum calcium and decrease serum parathormone, compared to what is observed after oral intake of a vehicle. However, significant differences in suppression of parathormone are observed between the different calcium preparations and might be of importance for their clinical use. [less ▲]

Detailed reference viewed: 28 (3 ULiège)
Full Text
Peer Reviewed
See detailPrediction of Bone Loss Rate in Healthy Postmenopausal Women
Reginster, Jean-Yves ULiege; Deroisy, Rita ULiege; Collette, Julien ULiege et al

in Calcified Tissue International (1997), 60(3), 261-4

Prevention of fractures is the only way to drastically reduce osteoporosis-related health expenditures. In order to optimize the cost/benefit ratio of a strategy of prevention, it is essential to identify ... [more ▼]

Prevention of fractures is the only way to drastically reduce osteoporosis-related health expenditures. In order to optimize the cost/benefit ratio of a strategy of prevention, it is essential to identify, as early as possible, women who will develop fractures later in their life. Therefore, and since postmenopausal bone loss is an asymptomatic process, screening procedures should detect, at the time of the menopause, women whose postmenopausal bone loss is higher than the mean, and will, a couple of years later, exhibit a low mineral content and a subsequent high risk for fractures. For 3 years we have followed a cohort of 92 healthy women who had undergone menopause less than 36 months previously. By a multivariate discriminant analysis based on the differences in lumbar bone density, assessed by dual photon absorptiometry, and in a few routine biochemical parameters (serum phosphorus, estrone, androstenedione, and urine calcium) observed during the first 6 months of the study, we have been able to correctly predict the rate of spinal bone loss, observed at the end of the 3 years, in 76% of the subjects. All of the women who presented a bone loss higher than 10% over the 3 years were correctly isolated by our discriminant functions after 6 months of follow-up. We conclude that a measurement of lumbar bone mineral density coupled with a few routine biochemical determinations, repeated twice at a 6-month interval in healthy postmenopausal women, can isolate 100% of postmenopausal "fast bone losers" with an overall specificity of 76%. [less ▲]

Detailed reference viewed: 25 (5 ULiège)
Peer Reviewed
See detailThe role of bisphosphonates in the treatment of osteoporosis
Reginster, Jean-Yves ULiege; Halkin, V.; Gosset, Christiane ULiege et al

in Drugs of Today (Barcelona, Spain : 1998) (1997), 33

Detailed reference viewed: 12 (0 ULiège)
Full Text
Peer Reviewed
See detailPrévention de l’ostéoporose à Liège. Histoire d’un PIGEPS : dix ans plus tard.
Reginster, Jean-Yves ULiege; DEROISY, Rita ULiege; LECART, Marie-Paule ULiege et al

in Santé Publique : Revue Multidisciplinaire pour la Recherche et l'Action (1996), 2

Detailed reference viewed: 64 (3 ULiège)
Full Text
Peer Reviewed
See detailFemoral osteoporosis in community-dwelling elderly females and controls living in retirement or nursing homes
DEROISY, Rita ULiege; Zheng, XS; Pirenne, H et al

in Osteoporosis International (1996), 6(S1), 118

Detailed reference viewed: 7 (1 ULiège)
Full Text
Peer Reviewed
See detail25-OH vitamin D deficiencies and secondary hyperparathyroidism in elderly women living at home or in nursing/retirement homes
DEROISY, Rita ULiege; Zheng, XS; Pirenne, H et al

in Osteoporosis International (1996), 6(S1), 119

Detailed reference viewed: 6 (1 ULiège)
Full Text
Peer Reviewed
See detail25-OH vitamin D levels in healthy ambulatory postmenopausal women
DEROISY, Rita ULiege; Albert, Adelin ULiege; Zheng, SX et al

in Osteoporosis International (1996), 6(S1), 119

Detailed reference viewed: 16 (3 ULiège)
Full Text
Peer Reviewed
See detailPrevention of early postmenopausal bone loss with oral tiludronate
Roux, C; DEROISY, Rita ULiege; Basse-Cathalinat, B et al

in Osteoporosis International (1996), 6(S1), 249

Detailed reference viewed: 34 (2 ULiège)
Full Text
Peer Reviewed
See detailPlasma Concentration of Estradiol Following Transdermal Administration of Systen 50 or Menorest 50
Reginster, Jean-Yves ULiege; Albert, Adelin ULiege; Deroisy, Rita ULiege et al

in Scandinavian Journal of Rheumatology. Supplement (1996), 103

Circulating levels of 17 beta estradiol (E2) following the administration of fixed doses of E2, show a great variability in kinetics depending upon the product administrated, the routes of administration ... [more ▼]

Circulating levels of 17 beta estradiol (E2) following the administration of fixed doses of E2, show a great variability in kinetics depending upon the product administrated, the routes of administration, and the interindividual variations in absorption and metabolism. This might have important implications both in terms of tolerance and effectiveness. Two new forms of transdermal E2 (SYSTEN Cilag and MENOREST Rhone-Poulenc Rorer) have been recently accepted in Europe for the treatment of climacteric symptoms. The present study was undertaken to compare the pharmacokinetic characteristics of plasma E2 profile under these two drugs. It was carried out in 30 healthy postmenopausal volunteers according to good clinical practice after informed consent, as a single blind, randomised, cross-over study during the classical wearing period of 4 days. Plasma E2 concentration was determined 24 hours before, 1/2 hour before and then 2, 4, 8, 12, 24, 48, 72, 84, 96 hours after the first patch administration. E2 measurement was performed using a specific direct radioimmunoassay developed in the FRH laboratories. The main criteria for this method were an intraassay coefficient of variation (CV) less than 6%, an interassay CV less than 8% in a concentration range of 15-140 pg/ml and a quantitative detection limit (LOQ) of 2.7 pg/ml with a 20% CV. The following kinetic parameters were analysed: C(max), C(mean), C96 and MRT. The bioequivalence was assessed by analysis of variance of C(max), C(mean), C96 and AuC after logarithmic transformation, complemented by Westlake test (95%). Data show that these two products are identical in terms of C(max) but C(mean), C96 and AuC are statistically greater when MENOREST 50(R) is administered; furthermore, E2 levels decrease more rapidly and more deeply with SYSTEN 50 than MENOREST 50. The differences of pharmacokinetic profiles after administration of two different forms of the same dose of 50 micrograms transdermal 17 beta estradiol might have important medical consequences. [less ▲]

Detailed reference viewed: 40 (7 ULiège)
Full Text
Peer Reviewed
See detailPrevention of Postmenopausal Bone Loss by Rectal Calcitonin
Reginster, Jean-Yves ULiege; Jupsin, Isabelle ULiege; Deroisy, Rita ULiege et al

in Calcified Tissue International (1995), 56

A group (150) of healthy women, who had been menopausal for less than 5 years and who had never received any form of treatment to prevent bone loss were entered into a randomized, controlled study ... [more ▼]

A group (150) of healthy women, who had been menopausal for less than 5 years and who had never received any form of treatment to prevent bone loss were entered into a randomized, controlled study comprising three arms. They were randomly allocated to the double-blind administration of five suppositories per week containing either 100 IU of salmon calcitonin or a placebo, or to a group receiving a suppository containing 200 IU of salmon calcitonin three times per week. All women received 500 mg/day of calcium supplementation. After 12 months, bone mineral density (BMD) of the spine, measured by dual energy X-ray absorptiometry, decreased significantly (P < 0.01) in the placebo group by 3.1% (SD: 3.6%) but did not change in the two calcitonin groups [+1.3% (3.5%) with 100 IU/day and +2.3% (4.0%) with 200 IU 3/week]. The differences in response between the placebo group and the two calcitonin groups were significant (P < 0.05), but the difference between the two regimens of calcitonin administration was not. No differences appeared among the three groups for the response at the level of the hip. Evolution of biochemical markers reflecting bone turnover did not differ significantly among groups. Nearly 40% of the women withdrew prematurely because of local (rectal or intestinal) intolerance to repetitive suppositories, with a nonsignificantly different frequency in the placebo or calcitonin groups. We conclude that rectal calcitonin might be an interesting preventive approach against trabecular postmenopausal bone loss but that long-term acceptability of suppositories should be evaluated in view of each patient's sensibility or cultural background. [less ▲]

Detailed reference viewed: 11 (2 ULiège)